Adagene (FRA:978) Research & Development: €18.97 Mil (TTM As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.48
GF Value €11.94
! 5 Warning Signs
View Full Analysis

What is Adagene Research & Development?

Adagene FRA:978 +4.82% 42 Research & Development is €18.97 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.94. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adagene's Research & Development for the six months ended in Dec. 2025 was €8.56 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €18.97 Mil.

Adagene  (FRA:978) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adagene Research & Development Related Terms

Adagene Research & Development Historical Data

* Premium members only.

The historical data trend for Adagene's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Research & Development Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 60.27 76.79 33.60 27.49 18.82

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.08 13.68 13.42 10.42 8.56
FRA:978
42GF Score
Adagene Inc FRA:978
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €18.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €18.97 Mil mean?
Adagene (FRA:978) has a Research & Development of €18.97 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Adagene and its competitors.
Is Adagene's Research & Development too high?
Adagene's current Research & Development is €18.97 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Research & Development compare to CNTX and TARA?
Adagene's Research & Development of €18.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adagene and its competitors. Adagene's current Research & Development is €18.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Research & Development of €18.97 Mil. The stock's GF Value™ is €11.94, compared to a current price of €3.48 — trading 70.9% below its estimated fair value. The current Research & Development is €18.97 Mil. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adagene (FRA:978), the current Research & Development is €18.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.48 is trading 70.9% below its estimated GF Value™ of €11.94.

Key valuation signals for FRA:978:

  • Research & Development: €18.97 Mil
  • GF Value™: €11.94 vs. price of €3.48 (70.9% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€11.94
GF Value